Internal Medicine Unit, San Bortolo Hospital, Vicenza, Italy.
Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, Florida, USA.
Clin Endocrinol (Oxf). 2023 Jul;99(1):17-34. doi: 10.1111/cen.14918. Epub 2023 Apr 20.
Complete resolution of hypertension (CRH) after adrenalectomy for primary aldosteronism is far from a certainty. Although several prognostic models have been proposed to predict outcome after adrenalectomy, studies have not clarified which of the available models can be used reliably in clinical practice. To identify, describe and appraise all prognostic models developed to predict CRH, and meta-analyse their predictive performances. We searched MEDLINE, Embase and Web of Science for development and validation studies of prognostic models. After selection, we extracted descriptive statistics and aggregated area under the receiver operator curve (AUC) using meta-analysis. From 25 eligible studies, we identified 12 prognostic models used for predicting CRH after total adrenalectomy in primary aldosteronism. We report the results for 3 models that had available data from at least 3 external validation studies: the primary aldosteronism surgical outcome (PASO) score (AUC: 0.81; 95% confidence interval [CI]: 0.74-0.86; 95% predictive interval [PI]: 0.04-1.00), Utsumi nomogram (AUC: 0.79; 95% CI: 0.72-0.85; 95% PI: 0.03-1.00) and the aldosteronoma resolution score (ARS) model (AUC: 0.77; 95% CI: 0.74-0.80; 95% PI: 0.59-0.86 for all studies and AUC: 0.80; 95% CI: 0.75-0.85; 95% PI: 0.57-0.93 for the studies with the same adrenal vein sampling-guided adrenalectomy rate compared to the models meta-analysed). The PASO score, Utsumi nomogram and ARS model showed comparable discrimination performance to predict CRH in primary aldosteronism. Unlike the ARS model, the number of external validation studies for the PASO score and the Utsumi nomogram was relatively low to draw definite conclusions.
原发性醛固酮增多症患者经肾上腺切除术治疗后,高血压完全缓解(CRH)的情况远非确定无疑。尽管已经提出了几种预测肾上腺切除术治疗结局的预后模型,但研究仍未阐明哪些现有的模型可在临床实践中可靠地应用。本研究旨在识别、描述和评估所有旨在预测 CRH 的预后模型,并对其预测性能进行荟萃分析。我们检索了 MEDLINE、Embase 和 Web of Science 以获取用于开发和验证预后模型的研究。经过筛选,我们提取了描述性统计数据,并使用荟萃分析汇总了接收者操作特征曲线(ROC)下的面积(AUC)。在 25 项符合条件的研究中,我们确定了 12 项用于预测原发性醛固酮增多症患者行肾上腺全切术后 CRH 的预后模型。我们报告了 3 项具有至少 3 项外部验证研究可用数据的模型的结果:原发性醛固酮增多症手术结局(PASO)评分(AUC:0.81;95%置信区间 [CI]:0.74-0.86;95%预测区间 [PI]:0.04-1.00)、Utsumi 列线图(AUC:0.79;95%CI:0.72-0.85;95%PI:0.03-1.00)和醛固酮瘤缓解评分(ARS)模型(AUC:0.77;95%CI:0.74-0.80;95%PI:0.59-0.86 适用于所有研究,AUC:0.80;95%CI:0.75-0.85;95%PI:0.57-0.93 适用于与模型荟萃分析相比采用相同肾上腺静脉采样指导的肾上腺切除术率的研究)。PASO 评分、Utsumi 列线图和 ARS 模型在预测原发性醛固酮增多症患者的 CRH 方面表现出相当的判别性能。与 ARS 模型不同,PASO 评分和 Utsumi 列线图的外部验证研究数量相对较少,无法得出明确结论。